Predictors of pain medication selection among patients diagnosed with fibromyalgia
Pain Practice, 04/19/2012Boulanger L et al.
The presence of select comorbidities and prior use of certain medications were associated with the duloxetine initiation among working–age, commercially insured patients with fibromyalgia.
Administrative claims from a large, U.S. commercially insured population were analyzed using a retrospective cohort design.
Patients with fibromyalgia who were 18 to 64 years old and initiated duloxetine vs. selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, gabapentin, pregabalin, tramadol, or nontramadol opioids between January 1, 2007 and December 12, 2008 were selected.
Treatment initiation was defined as no access to the same medication over the previous 90 days, with the most recent initiation date as the index date.
All patients selected had at least one fibromyalgia diagnosis (ICD–9–CM: 729.1) in the 12 months prior to initiation of each study medication.
Multiple logistic regression models were estimated to assess the predictors of initiating duloxetine vs. each of the other medications.
The study included 117,305 patients with fibromyalgia (48 years of age on average; 76% women) who initiated duloxetine (n = 5,827), SSRIs (n = 8,620), TCAs (n = 5,424), venlafaxine (n = 2,038), gabapentin (n = 5,733), pregabalin (n = 11,152), tramadol (n = 7,312), or nontramadol opioids (n = 71,199).
Common fibromyalgia–related comorbidities were low back pain (31% to 49%), osteoarthritis (14% to 21%), and sleep disturbance (10% to 15%).
Controlling for demographic and clinical characteristics, patients who received pregabalin in the prior 12–month period were more likely to initiate duloxetine.
Patients from other treatment cohorts, except for those in the pregabalin and nontramadol opioid cohorts, were more likely to re–initiate the same prior medication than to begin treatment with duloxetine.
Other predictors of duloxetine initiation included history of rheumatoid and sleep disturbance.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.